6.48

5.48% -0.27

After Hours: 6.45 -0.03 -0.46%

Cartesian Therapeutics Inc (RNAC)

Overview News Price History Option Chain Financials Discussions Forecast

Cartesian Therapeutics Inc stock is traded at $6.48, with a volume of 358.58K. It is down -5.48% in the last 24 hours and down -5.48% over the past month. Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.

Previous Close:

$6.75

Open:

$6.87

24h Volume:

358.58K

Relative Volume:

1.68

Market Cap:

$188.63M

Revenue:

$1.78M

Net Income/Loss:

$-151.77M

P/E Ratio:

-1.1176

EPS:

-5.7981

Net Cash Flow:

$-79.40M

1W Performance:

+4.76%

1M Performance:

-5.48%

6M Performance:

-16.05%

1Y Performance:

-30.35%

1-Day Range:

$6.04

$7.37

1-Week Range:

$6.04

$7.37

52-Week Range:

$5.60

$15.57

Cartesian Therapeutics Inc Stock (RNAC) Company Profile

Name

Cartesian Therapeutics Inc

Sector

Healthcare (1113)

Industry

Biotechnology (618)

Phone

301-348-8698

Address

7495 NEW HORIZON WAY, FREDERICK

Employee

Twitter

Next Earnings Date

2026-05-14

Latest SEC Filings

RNAC's Discussions on Twitter

Compare RNAC vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RNAC Cartesian Therapeutics Inc	6.42	198.33M	1.78M	-151.77M	-79.40M	-5.7981
VRTX Vertex Pharmaceuticals Inc	435.92	110.28B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	634.42	66.98B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	808.61	50.15B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	295.50	39.71B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	154.89	32.22B	742.00K	-1.37B	-1.07B	-7.0731

Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-09-26	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Jul-09-25	Initiated	Wedbush	Outperform
Dec-19-24	Initiated	BTIG Research	Buy
Aug-06-24	Initiated	TD Cowen	Buy
Jul-02-24	Downgrade	Oppenheimer	Outperform → Perform
Jun-04-24	Initiated	Oppenheimer	Outperform
May-24-24	Initiated	Mizuho	Buy
Apr-23-24	Reiterated	H.C. Wainwright	Buy
Apr-23-24	Initiated	Leerink Partners	Outperform
Aug-18-23	Downgrade	SVB Securities	Outperform → Market Perform
Jun-14-22	Reiterated	Needham	Buy
Jun-06-22	Initiated	SVB Leerink	Outperform
Jun-15-21	Initiated	BTIG Research	Buy
Jan-26-21	Upgrade	Mizuho	Neutral → Buy
Oct-01-20	Downgrade	Mizuho	Buy → Neutral
Oct-01-20	Downgrade	William Blair	Outperform → Mkt Perform
Jun-12-20	Downgrade	Stifel	Buy → Hold
Apr-28-20	Initiated	H.C. Wainwright	Buy
Jan-29-20	Initiated	Cantor Fitzgerald	Overweight
Jan-21-20	Initiated	William Blair	Outperform
Jun-27-18	Initiated	Janney	Buy
Mar-30-17	Reiterated	UBS	Buy

View All

Cartesian Therapeutics Inc Stock (RNAC) Latest News

01:16 AM

RNAC Maintained by Needham -- Price Target Lowered to $40.00 - GuruFocus

01:16 AM

11:40 AM

Cartesian Therapeutics stock price target maintained at $40 by Mizuho - Investing.com Canada

11:40 AM

11:03 AM

Cartesian Therapeutics secures up to $150 million financing - The Pharma Letter

11:03 AM

09:05 AM

Cartesian Therapeutics secures $150M non-dilutive financing, advancing CAR-T trials with key data expected in 2027. - Pluang

09:05 AM

08:58 AM

Cartesian Therapeutics Secures $150 Million Loan Agreement with K2 HealthVentures and Ankura Trust Company - Minichart

08:58 AM

08:33 AM

Cartesian Therapeutics (RNAC) Secures $150M Credit Facility for Growth Initiatives - GuruFocus

08:33 AM

07:54 AM

Cartesian Therapeutics Lands Up to $150 Million in Non-Dilutive Financing to Support CAR-T Commercialization Push - citybiz

07:54 AM

07:45 AM

Cartesian Therapeutics IncEnters loan and security agreement on May 22SEC filing - marketscreener.com

07:45 AM

07:41 AM

Cartesian Secures Major Loan Facility to Extend Runway - TipRanks

07:41 AM

07:18 AM

Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027 - The Manila Times

07:18 AM

07:13 AM

Milos Miljkovic to Depart Cartesian Therapeutic as Chief Medical Officer; Separation Agreement Expected - TradingView

07:13 AM

07:10 AM

Cartesian Therapeutics secures up to 150 million dollar credit facility to extend cash runway to 2028 - Traders Union

07:10 AM

07:08 AM

Cartesian Therapeutics (NASDAQ: RNAC) adds $150M credit line and extends cash runway - Stock Titan

07:08 AM

07:00 AM

Up to $150M backs CAR-T for myasthenia gravis, data in 2027 - Stock Titan

07:00 AM

May 21, 2026

Cartesian Therapeutics (RNAC) Q1 2026 Earnings Miss: Breaking Down the NumbersEarnings Revision Upgrade - Newser

May 21, 2026

Cartesian Therapeutics (RNAC) Q1 2026 Earnings: Soft Quarter Raises QuestionsCollaborative Trading Signals - Newser

May 21, 2026

May 19, 2026

Cartesian Therapeutics (RNAC) Drops -7.33% — Key Support at $6.07 2026-05-19Investment Signal Network - newser.com

May 19, 2026

May 18, 2026

Myasthenia Gravis Market Set to Surpass USD 16 Billion by 2036, Fueled by Rising Diagnosed Prevalence and Wave of Targeted Biologic Approvals | DelveInsight - GlobeNewswire Inc.

May 18, 2026

May 17, 2026

Today's Analyst Ratings: Needham Reiterates Buy Rating for RNAC - GuruFocus

May 17, 2026

We're Keeping An Eye On Cartesian Therapeutics' (NASDAQ:RNAC) Cash Burn Rate - Yahoo Finance

May 17, 2026

May 14, 2026